

1
2
3
4 **Polysaccharides from Wolfberry Antagonizes Glutamate Excitotoxicity**
5
6
7 **in Rat Cortical Neurons**

8
9
10
11 Yuen-Shan Ho^{1,2}, Man-Shan Yu¹, Suet-Yi Yik¹, Kwok-Fai So^{1,2,3},
12
13 Wai-Hung Yuen⁴ and Raymond Chuen-Chung Chang^{1,2,3*}
14
15

16
17
18 ¹Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of
19
20 Medicine;

21
22
23 ²Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine;

24
25 ³State Key Laboratory of Brain and Cognitive Sciences;

26
27 ⁴Department of Chemistry,

28
29 The University of Hong Kong, Pokfulam, Hong Kong SAR, CHINA
30
31
32
33
34
35
36
37
38
39
40

41 **Keywords:** Wolfberry / neuroprotection / glutamate / excitotoxicity / c-Jun N-terminal kinase
42
43
44

45
46 ***Correspondence address:**
47

48 Dr. Raymond C. C. Chang, Department of Anatomy, Faculty of Medicine,
49

50 The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR,
51

52 CHINA
53

54
55 Tel: (+852) 2819-9127; Fax: (+852) 2817-0857; E-mail: rcchang@hkucc.hku.hk
56
57
58
59
60
61
62
63
64
65

Abstract

Glutamate excitotoxicity is involved in many neurodegenerative diseases including Alzheimer's disease (AD). Attenuation of glutamate toxicity is one of the therapeutic strategies in AD treatment. Wolfberry (*Lycium barbarum*) is a common ingredient in oriental cuisines. In recent years, there is a trend of using dried Wolfberry as food supplement and health product in U.K. and North America. A number of studies suggest that wolfberry has anti-aging properties. Previously, we have demonstrated that a fraction of polysaccharide from Wolfberry (LBA) provided remarkable neuroprotective effects against beta-amyloid peptide-induced cytotoxicity in primary cultures of rat cortical neurons. To investigate whether LBA can protect neurons from other pathological factors such as glutamate found in Alzheimer brain, we examined whether it can prevent neurotoxicity elicited by glutamate in primary cultured neurons. The glutamate-induced cell death as detected by lactate dehydrogenase (LDH) assay and caspase-3-like activity assay was significantly reduced by LBA at concentrations ranged from 10 to 500 $\mu\text{g/ml}$. Protective effects of LBA were comparable to memantine, a non-competitive NMDA receptor antagonist. LBA provided neuroprotection even 1 h after exposure to glutamate. In addition to glutamate, LBA attenuated N-methyl-D-aspartate (NMDA)-induced neuronal damage. To further explore whether LBA might function as antioxidant, we used hydrogen peroxide (H_2O_2) as oxidative stress inducer in this study. LBA could not attenuate the toxicity of H_2O_2 . Furthermore, LBA did not attenuate glutamate-induced oxidation by using NBT assay. Western blot analysis indicated that glutamate-induced phosphorylation of c-jun N-terminal kinase (JNK) was reduced by treatment with LBA. Taken together, LBA exerted significant neuroprotective effects on cultured cortical neurons exposed to glutamate.

1. Introduction

Glutamate is an excitatory amino acid and plays important roles in neurotransmission. It is also involved in a wide array of physiological processes including synaptogenesis, neuronal plasticity, learning and memory (Miyamoto, 2006; Shigeri *et al.*, 2004). In physiological conditions, the concentration of glutamate in synapses is tightly controlled. Abnormal high concentrations of glutamate result in neuronal cell damage, which can be found in brain injury, hypoxia, ischemia, Alzheimer's disease (AD), Parkinson's disease and Huntington's disease (Arundine and Tymianski, 2004; Coyle and Puttfarcken, 1993; Won *et al.*, 2002).

Two major mechanisms have been proposed for the neurotoxicity of glutamate. The first one is glutamate-receptor mediated excitotoxicity, which is mainly contributed by the activation of ionotropic glutamate receptors. The subsequent influx of Ca^{2+} can cause both necrotic and apoptotic cell death (Choi *et al.*, 1987; Hyrc *et al.*, 1997). The second mechanism is the induction of oxidative stress by glutamate (Shih *et al.*, 2006; Schubert and Piasecki, 2001). High concentrations of glutamate in synapses can inhibit the cysteine/glutamate antiporter x_c^- ; and therefore attenuating uptake of cysteine. Since cysteine is required for the synthesis of glutathione (GSH), depletion of glutathione by extracellular glutamate results in accumulation of oxidative stress and programmed cell death (Schubert and Piasecki, 2001; Tan *et al.*, 1998; Tan *et al.*, 2001).

As glutamate neurotoxicity is involved in the pathogenesis of AD, reduction of glutamate-toxicity is one of the possible therapeutic targets (Pietrzik and Behl, 2005; Gardoni and Di, 2006). Several drugs targeting glutamate toxicity are under development for the treatment of AD. An example is memantine, a non-competitive NMDA antagonist, for the

1
2
3
4 treatment of moderate to severe AD (Golde, 2006). In fact, some compounds or extracts from
5
6 daily food can also protect neurons against glutamate-toxicity. Curcumin is a principle
7
8 polyphenol which is responsible for the yellow color of the Indian curry spice turmeric.
9
10 Studies have shown that it protects primary cultured neurons from glutamate-induced cell
11
12 death, probably by inhibiting PKC activity, and subsequent phosphorylation of NR1 of the
13
14 NMDA receptor (Yazawa *et al.*, 2006). The green tea extract EGCG may also provide
15
16 protection against glutamate by enhancing glutamate uptake and S100B secretion from
17
18 astrocytes (Abib *et al.*, 2008). It is therefore possible to develop disease-modifying agent that
19
20 have neuroprotective function against glutamate excitotoxicity from daily food.
21
22
23
24
25
26

27 Wolfberry, the fruits of *Lycium barbarum*, has long been used as a common ingredient
28
29 in oriental cuisines. It has a high content of zeaxanthin, which probably enable it to improve
30
31 and maintain vision. In recent years, there is a trend of using Wolfberry as food supplement
32
33 and health product in U.K. and North America. For example, the juice of Wolfberry, called
34
35 Goji juice, is a commercially available product which claims to be beneficial to our health and
36
37 slow down aging. A recent randomized, double-blinded clinical study has shown that it can
38
39 increase subjective feelings of general well-being and improves neurologic/psychologic
40
41 performance (Amagase and Nance, 2008). Whether Goji juice is as beneficial as it claims
42
43 remains a question, some research focused on the Wolfberry extracts and its different
44
45 components demonstrated that they provided diverse biological effects. Recent evidence on
46
47 its anti-aging effects have suggested that it is neuroprotective in various aging-associated
48
49 pathological conditions (Chan *et al.*, 2007; Chang and So, 2008; Ho *et al.*, 2007; Li *et al.*,
50
51 2007; Yu *et al.*, 2005; Yu *et al.*, 2006). The major active component from Wolfberry is
52
53 polysaccharide. Previously, our laboratory has demonstrated that a fraction of polysaccharides
54
55 from Wolfberry (LBA) elicits neuroprotective effects against beta-amyloid (A β) peptide
56
57
58
59
60
61
62
63
64
65

1
2
3
4 toxicity (Ho et al., 2007; Yu et al., 2005). To further examine whether LBA can serve as
5
6 disease-modifying agent against degeneration in AD, we investigated its protective effects
7
8 against glutamate excitotoxicity. It is possible that LBA may protect neurons against other
9
10 Alzheimer's disease-related pathological conditions. We hypothesize that LBA exerts
11
12 cytoprotective effects against glutamate toxicity.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Results

2.1. Protective effects of LBA against glutamate-induced cell death

To examine the toxicity of glutamate, cortical neurons were exposed to 30 or 60 μ M glutamate. Cultured neurons have a normal turnover with baseline LDH of 12.5 ± 0.5 % of total lysis. Exposure to 30 or 60 μ M glutamate elevated LDH release to 2.7 ± 0.2 fold of control or 3.3 ± 0.2 fold of control, respectively (Fig 1c, 1e). Exposure to LBA markedly reduced glutamate neurotoxicity in concentration-dependent manner. LBA at 500 μ g/ml significantly abrogated cell death-induced by glutamate (Fig 1c, 1e).

Glutamate also induced apoptotic cell death as indicated by activation of caspase-3. The specific activity of caspase-3 was 0.042 ± 0.007 pmol/min/ μ g of protein in our control group. Glutamate at 30 or 60 μ M elevated activities of caspase-3 by 1.6 ± 0.1 or 1.8 ± 0.1 fold of control, respectively (Fig. 1d, 1f). Treatment of LBA significantly decreased glutamate-triggered activity of caspase-3. The effective dosages of LBA to attenuate glutamate toxicity were ranged from 10 to 500 μ g/ml, which was wider than that observed by LDH assay. One has to notice that activation of caspase-3 is on of the processes in apoptosis, while LDH is the end-product assay of necrosis. Therefore a high dose of LBA is required for reducing LDH release. We did not have any intention to makes correlation between LDH release and capsase-3 activity, but serving as index for different mode of death (Baethmann *et al.*, 1996).

The protective effects of LBA on glutamate-induced cell death were supported by examining neuronal morphology. Representative images showing the protective effects of LBA against 24 h of exposure to glutamate are depicted in Fig. 2. Exposure to glutamate led to shrinkage of cell body and breakage of neurites (Fig. 2b and 2c). In LBA-treated groups (Fig. 2 e and 2f), neuronal cell maintained their integrity and fasciculation of neurites.

1
2
3
4
5
6 LBA itself had no significant effect on LDH and caspase-3 activity (Fig. 1a and 1b);
7
8 and there was no obvious morphological difference between the control and LBA groups (Fig.
9
10
11 2d).

12 13 14 15 *2.2. Comparison of LBA and memantine in attenuating glutamate excitotoxicity*

16
17 To examine the effectiveness of LBA in glutamate-induced cell death, we used
18 memantine as positive control. Memantine is a drug approved by the European Union and the
19 U.S. Food and Drug Administration (FDA) for the treatment of AD. The mechanism for its
20 action is partly because it is a non-competitive and low-affinity NMDA antagonist (Lipton,
21 2005; Johnson and Kotermanski, 2006). The neuroprotective effects of LBA and memantine
22 against glutamate-excitotoxicity were compared. We used memantine for comparison because
23 we would like to know the efficacy of LBA in attenuating glutamate toxicity. Preliminary
24 trials were carried out to determine the most effective and non-toxic dosages for memantine
25 against glutamate toxicity (data not shown). The maximum dosage of memantine used in this
26 study was 1 μ M, which is the usual therapeutic plasma concentration in AD patients
27 (Kornhuber and Quack, 1995; Parsons et al., 2008). Fig. 3a shows the protective effects of
28 LBA and memantine against glutamate-induced LDH release. Both LBA and memantine
29 could significantly attenuate release of LDH, and their protective effects were comparable.
30
31 Similar results were observed in 30 μ M glutamate-mediated activation of caspase-3 (Fig. 3b).
32 Both LBA and memantine could almost completely reduce activity of caspase-3 triggered by
33 30 μ M glutamate. However, only LBA provided protection against 60 μ M glutamate as
34 indicated by the reduction of level of caspase-3 from 1.8 ± 0.1 fold to 1.2 ± 0.1 fold of control.
35
36 Memantine at 1 μ M did not elicit protection against 60 μ M glutamate-mediated activation of
37 caspase-3.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.3. Post-treatment of LBA

In order to examine the possible neuroprotective properties of LBA, post-treatment experiments were performed, in which LBA was added into the culture 1 h after their exposure to glutamate. Post-treatment of LBA at 100 $\mu\text{g/ml}$ led to a $20.9 \pm 2.4\%$ and $22.9 \pm 3.2\%$ reduction in 60 μM glutamate-triggered LDH release and activity of caspase-3, respectively (Fig 4c & d). However, only 250 $\mu\text{g/ml}$ of LBA could significantly attenuate caspase-3 activity triggered by 30 μM glutamate (Fig 4b). We are surprised that protective behavioral in pretreatment and post-treatment was very different, further suggested that the mechanisms of necrosis was different to that of apoptosis. Furthermore, it appeared that 30 μM and 60 μM glutamate utilized different toxic pathways for toxic effects. When the protective effects between the pretreatment and post-treatment experiments were compared, we found that pretreatment was more effective than post-treatment.

2.4. LBA attenuated NMDA-induced neuronal cell death

Previous studies suggested that activation of NMDA receptor is a key factor for glutamate neurotoxicity (Coyle and Puttfarcken, 1993). In order to find out whether LBA could protect neurons against NMDA-induced neuronal damage, neurons were treated with LBA and then NMDA. After 24 h of 40 or 60 μM NMDA exposure, there were increase in LDH release for 1.4 ± 0.1 or 1.6 ± 0.1 fold of control, respectively (Fig. 5a). LBA significantly attenuated NMDA-triggered LDH release in dose-dependent manner. Exposure of neurons to 40 or 60 μM NMDA-induced apoptosis as indicated by the elevation of the activity of caspase-3 by 1.4 ± 0.1 or 1.7 ± 0.1 fold of control, respectively (Fig. 5b). LBA significantly attenuated the activity of caspase-3 induced by 60 μM NMDA. However, LBA could not significantly inhibit caspase-3 triggered by 40 μM NMDA. Similar to what we

1
2
3
4 observed in glutamate, the mechanisms mediating necrosis and apoptosis are somewhat
5
6 different. Furthermore, it was possible that different pathways mediating low or high
7
8 concentration of NMDA toxicity.
9

10 11 12 13 *2.5. LBA did not function as anti-oxidant*

14
15 Oxidative stress is one of the secondary factors mediating glutamate neurotoxicity;
16
17 and therefore it is a possible therapeutic target. One may suspect of whether LBA have anti-
18
19 oxidative properties which would account for its protective effects. In order to investigate this
20
21 property, we examined if LBA could protect neurons against hydrogen peroxide, a typical
22
23 oxidative stress inducer. As indicated in Fig. 6, hydrogen peroxide induced neuronal damage
24
25 as reflected by an increase in LDH release and caspase-3 activity by 1.3 ± 0.1 and 1.5 ± 0.1
26
27 folds of control, respectively. LBA did not exert protective effect against hydrogen peroxide.
28
29 In contrast to have no protective effects on H_2O_2 toxicity, LBA at 10 or 100 $\mu\text{g/ml}$
30
31 significantly increased caspase-3 activity. The results may imply that free radicals may
32
33 change conformation of LBA at some concentrations to abolish protective effects of LBA.
34
35
36
37
38
39

40 To further confirm whether LBA suppressed production of free radicals by glutamate,
41
42 we employed NBT reduction assay to examine intracellular free radicals. Our results showed
43
44 that there was a 58% increase of intracellular ROS (Fig. 7). LBA did not attenuate
45
46 intracellular ROS level, which further support the notion that LBA did not function as
47
48 antioxidant to protect neurons in glutamate excitotoxicity.
49
50
51
52
53

54 *2.6. LBA attenuated phosphorylation of JNK triggered by glutamate*

55
56 JNK has been shown to be one of the signaling pathways being activated by glutamate
57
58 (Arthur *et al.*, 2007; Chen *et al.*, 2003; Chi *et al.*, 2005). Results from Western-blot analysis
59
60
61
62
63
64
65

1
2
3
4 showed that there was a significant increase in phosphorylation of JNK1, with little effect on
5
6 non-phosphorylated JNK1 (Fig. 8). LBA reduced phosphorylation of JNK1 dose-dependently
7
8 and this was consistent with its protective effects.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Discussion

In this study, we have demonstrated that exposure of primary cortical neurons to LBA prevents neuronal damage induced by glutamate and NMDA. Since disturbance of glutamate transmission is one of the pathological factors in dementia and degenerative processes, attenuation of glutamate excitotoxicity by LBA is an advantage to stop progression of disease. Therefore, we provide evidence here that LBA can be further explored of whether it can be developed as a potential candidate as disease-modifying agent for the treatment of AD.

It has been documented that glutamate can impose its toxicity on neurons in both necrotic and apoptotic manner (Portera-Cailliau *et al.*, 1997; Arthur *et al.*, 2007; Kogo *et al.*, 2006). Our results indicate that excitotoxic glutamate triggered release of LDH from neurons; and this is significantly blocked by LBA. LBA also attenuates NMDA toxicity as reflected by the attenuation of the release of LDH. With the use of NMDA antagonist MK801, we found that glutamate neurotoxicity was attenuated (data not shown). This suggests that NR2A receptor pathway took part, at least in some degree, in glutamate-mediated excitotoxicity in our model.

Activation of caspases is believed to play a key role in glutamate-induced neuronal apoptosis (Zhang and Bhavnani, 2006; Amodio *et al.*, 2006). In agreement with previous studies, which show activation of caspase-3 in cortical, hippocampal (Zhang *et al.*, 2003) and cerebellar granular cells (Amodio *et al.*, 2006), our results also show activation of caspase-3. Inhibition of caspase-3 activation by LBA may partly contribute to its neuroprotective effects against glutamate-triggered neuronal apoptosis.

1
2
3
4 Generation of ROS is one of the pathological events during excitotoxicity. Following
5
6 influx of Ca²⁺, there are activation of phospholipase and NO synthase, resulting in high levels
7
8 of ROS and NO. The interaction of NO with superoxide radical leads to formation of reactive
9
10 peroxynitrite, which can be a cytotoxic mediator in excitatory neuronal injury (Gilgun-Sherki
11
12 et al., 2002). Since many herbal extracts have anti-oxidative properties, it is reasonable for
13
14 one to speculate that LBA may exert its protective effects by attenuating ROS generated by
15
16 glutamate. We found that LBA could not attenuate hydrogen peroxide toxicity, suggesting
17
18 that LBA may not provide strong anti-oxidative effects. At the same time, we found that LBA
19
20 treatment could not attenuate glutamate-induced ROS generation, which support the idea that
21
22 LBA may protect neurons independent on the anti-oxidative mechanism.
23
24
25
26
27
28

29 We further examined signaling pathways that are mediated by LBA for its protection.
30
31 Our previous study on LBA has demonstrated that it has anti-apoptotic properties on A β -
32
33 induced neuronal cell death, and this is probably mediated by of the JNK signaling pathway
34
35 (Yu et al., 2005). In fact, active JNK has been implicated in neuronal cell death under
36
37 different pathological insults such as stroke, epilepsy, traumatic brain injury and
38
39 neurodegenerative diseases (Choi, 1988). Similar to a previous report (Chen et al., 2003),
40
41 glutamate induces JNK1 phosphorylation at Thr 183 or Thr 185, with little changes in the
42
43 phosphorylation of JNK2. Since activation of glutamate receptors mediates physiological
44
45 functions other than its excitotoxicity, it has been suggested that downstream signaling events
46
47 rather than blockage of the receptors should be targeted (Borsello et al., 2003). Furthermore,
48
49 there are reports showing that strong NMDA antagonist such as MK801 (dizocilpine) and
50
51 phencyclidine can attenuate excitotoxicity; but in the same time induce adverse side effects
52
53 (Gladstone et al., 2002). Our results of LBA on suppression of JNK activation suggested that
54
55 it can be a potential candidate for therapeutic purpose.
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6 In this study, we chose memantine as a positive control and compared its protective
7
8 effect against glutamate neurotoxicity to that provided by LBA. We chose memantine instead
9
10 of other traditional extracts for comparison because memantine is a well defined compound
11
12 and it is an approved drug for the treatment of AD. More importantly, its pharmacokinetic
13
14 properties had been well studied (Kornhuber *et al.*, 2007). The normal plasma concentration
15
16 of memantine is 0.5-1 μ M, higher concentrations might increase the chance of adverse effects
17
18 (Freudenthaler and Pantev, 2008). Our data showed that the neuroprotective effects of LBA
19
20 against glutamate were comparable to that provided by highest dosage of memantine used in
21
22 this study. Although we compared LBA with memantine, our present data are not sufficient to
23
24 state that LBA functions as another NR2A antagonist or receptor modifier. Whether LBA
25
26 interferes with glutamate receptor functions remains unclear. Previous studies have shown
27
28 that LBA had diverse protective effects against neuronal damage induced by A β peptide as
29
30 well as dithiothreitol (DTT) (Yu *et al.*, 2005; Yu *et al.*, 2006), it is possible that LBA mediates
31
32 its protection in the receptor level. Polysaccharide is the major active component in LBA.
33
34 Recent research suggested that polysaccharide has various effects on the CNS and is involved
35
36 in long term potentiation, receptor regulation and neuronal development (Lauri *et al.*, 1999;
37
38 Sotogaku *et al.*, 2007). Regarding the receptor interaction, several reports have demonstrated
39
40 that polysaccharide is able to modify receptor properties (Sinnarajah *et al.*, 1999;
41
42 Suppiramaniam *et al.*, 2006). For instant, dextran sulfate, a polyanion that mimics natural
43
44 mucopolysaccharides such as heparin sulfate, is able to alter binding and channel properties of
45
46 AMPA receptors (Chicoine *et al.*, 2004). Apart from neuronal damage, over-stimulation on
47
48 AMPA receptors may also play a role in maintenance and repair of neurons (Dicou *et al.*,
49
50 2003; Wu *et al.*, 2004). Recent study has shown that polysaccharide can promote
51
52 neuroprotection against excitotoxicity by modulating the AMPA receptor signals (Chicoine
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 and Bahr, 2007). It is therefore possible for other neuroprotective polysaccharide to protect
5
6 neurons through modulation of AMPA receptor. More importantly, it has been documented
7
8 that neuroprotective polysaccharide such as hapan derivatives are able to pass through the
9
10 blood brain barrier (BBB) (Leveugle et al., 1998; Ma et al., 2002). Whether LBA is also able
11
12 to pass through BBB and interferes AMPA receptor has beyond the scope of our study, but
13
14 this certainly deserves further investigation.
15
16
17
18
19

20 We have demonstrated that LBA is able to reduce glutamate-induced neuronal damage.
21
22 Together with our previous findings that it has neuroprotective effects against A β toxicity, we
23
24 propose LBA has multiple benefits on the CNS. Its property of attenuating glutamate toxicity
25
26 enables it to extend its potential as disease-modifying agent for the treatment of a variety of
27
28 neurological disorders such as stroke, AD and glaucoma. In fact, our recent results have
29
30 shown that LBA provides protection for retinal ganglion cells in experimental glaucoma
31
32 (Chan et al., 2007). Furthermore, its protective effect against glutamate is comparable to that
33
34 of memantine, a drug that have been approved for treatment of AD. In summary, our findings
35
36 support the potential therapeutic use of LBA in neurological disorders, and more research is
37
38 needed to further explore its protective effects and underlying mechanisms.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4. Experimental Procedures

4.1. Materials

Wolfberry was purchased from Ning Xia Huizu Autonomous Region. The glycosyl composition and amino acid composition analysis were performed as described in Yu et al (2005).

NeurobasalTM medium, B-27 supplement, penicillin, streptomycin and glutamine were purchased from Gibco-BRL (Burlington, Ontario, Canada). Other chemicals were obtained from the following companies: L-glutamate, N-methyl-D-aspartate (NMDA), memantine, nitroblue tetrazolium (NBT) tablet, protease inhibitor cocktail, phosphatase inhibitor cocktail and anti- β -actin monoclonal antibody were obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Hydrogen peroxide was from BDH Laboratory Supplies (England). Lactate dehydrogenase (LDH) cytotoxicity assay kit was from Roche Diagnostics (Mannheim, Germany). Caspase-3 substrate (Ac-DEVE-pNA) was obtained from Calbiochem, Inc. (La Jolla, CA, USA). Rabbit polyclonal antibodies for JNK detection were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse antibodies were from DAKO (Glostrup, Denmark). PVDF membrane was from Bio-Rad (Richmond, CA, USA). Biomax X-ray film was from Kodak (Tokyo, Japan). Enhanced chemiluminescence (ECL) detection kit was from Amersham (Buckinghamshire, UK).

4.2. Preparation of Wolfberry polysaccharides (LBA)

LBA were prepared according to the previous publication (Yu et al., 2005). In brief, Wolfberry was crushed into small pieces and were extracted with boiling distilled water. After concentration and deproteination by the Sevag method (Seveg, 1934), the resulting aqueous

1
2
3
4 fraction was dialyzed, precipitated by ethanol. The retentate were then concentrated and dried
5
6 to yield a brown powder (LBA).
7
8
9

10 4.3. Preparation of primary cortical neurons and treatment 11

12
13 Cultures of rat embryonic day 17 cortical neurons were prepared as described
14
15 previously (Chang *et al.*, 2002; Suen *et al.*, 2003). Briefly, cortical neurons were micro-
16
17 dissected from the brains of rat fetuses in phosphate-buffered saline (PBS) with glucose (18
18
19 mM). Cells were subjected to mechanical trituration and were resuspended in Neurobasal™
20
21 medium containing 2% B-27, L-glutamine (2 mM), penicillin (50 U/ml) and streptomycin (50
22
23 µg/ml). Cells were seeded onto 6-well plates pre-coated with poly-L-lysine (25 µg/ml) at a
24
25 density of 1.0×10^6 /well. Neurons were maintained at 37°C in a humidified atmosphere of
26
27 5% CO₂, half of the medium in each well was replaced with fresh medium twice a week. On
28
29 day 7 *in vitro*, the cultured cells were treated with different dosages of LBA or memantine
30
31 prior to the exposure to glutamate, NMDA or hydrogen peroxide for 24 h. For post-treatment,
32
33 neurons were exposed to glutamate for 1 h and LBA were subsequently added into the
34
35 cultures for co-incubation of another 23 h.
36
37
38
39
40
41
42

43 4.4. Assessment of cell death 44

45 Cell death in various treatment groups was determined by the release of LDH into
46
47 supernatant of cell cultures. Activity of LDH was measured using a commercially available
48
49 kit as described elsewhere (Lai *et al.*, 2006; Yu *et al.*, 2005). Briefly, equal volume of cell free
50
51 culture supernatant and assay buffer were transferred into a 96-well-plate and incubated in
52
53 dark for 30 min at room temperature. Leakage of LDH into the culture medium was measured
54
55 at 492 nm wavelength. Results were expressed as fold of control (fold of control was
56
57 calculated as follow: $\text{absorbance}_{\text{of glutamate-treated/LBA-treated}} / \text{absorbance}_{\text{of control}}$).
58
59
60
61
62
63
64
65

4.5. Assessment of apoptosis

Apoptotic cell death was determined by measuring the caspase-3-like activity as described elsewhere (Fang *et al.* 2005; Yu *et al.* 2007). Proteins were extracted from cortical neurons using lysis buffer (5 mM DTT, 0.1 mM EDTA, 50 mM HEPES (pH 7.4) and 0.2% Triton-X-100) and the supernatant (lysate) was collected. Fifty micrograms of proteins from each sample and caspase-3 substrate (Ac-DEVD-pNA) were transferred to a 96-well-plate and incubated for 2 h at 37°C. During the reaction, a yellow product (pNA) was cleaved from the substrate (i.e. DEVD cleavage) and its absorbance at 405 nm was determined for caspase-3-like activity. The values of specific activity (s.a., unit = pmol/min/μg) were calculated. Results were expressed as fold of control.

4.6. Western blot analysis

Neurons after treatment were lysed in ice-cold lysis buffer (10 mM Tris-HCl (pH 7.4), 1 mM NaCl, 20 mM Na₄P₂O₇, 2 mM Na₃VO₄, 1% Triton-X-100, 10% glycerol, 0.5% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail and phosphatase inhibitor cocktail) and the supernatant was collected as described elsewhere (Lai *et al.* 2008; Suen *et al.* 2003; Yu *et al.* 2004). Equal amounts of protein were separated on 12.5% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% non-fat milk in TBST (TBS containing 0.1% Tween-20). Primary antibody specifically recognizing phosphorylated JNK (1:1000), non-phosphorylated JNK (1:1000) were diluted in TBST and incubated with the membrane overnight. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies, and subsequently developed by using the ECL Western blotting detection kit. The membranes were then stripped with stripping buffer (50 mM

1
2
3
4 glycine, 2% SDS, pH 2.0) and re-probed with monoclonal anti- β -actin antibody (1:5000) and
5
6 goat anti-mouse HRP secondary antibody.
7
8
9

10 4.7. Determination of ROS level

11
12
13 Production of ROS intracellularly was determined by the nitroblue tetrazolium (NBT)
14
15 reduction assay as described previously with some modifications (Choi *et al.*, 2005;
16
17 McDonald *et al.*, 1997; Chao *et al.*, 2008). The presence of ROS was indicated by the color
18
19 change of the water soluble NBT (yellow) to insoluble formazan (blue) upon reduction.
20
21 Cortical neurons were treated with different dosages of LBA for 1 h prior to the exposure of
22
23 glutamate. After 2 h of co-incubation, NBT (2 mg/ml) was added, and the cells were further
24
25 incubated for 1 h. Medium was removed and cultures were rinsed twice with ice-cold PBS to
26
27 remove excess NBT. The intracellular blue formazan was dissolved in dimethylsulfoxide
28
29 (DMSO) completely by sonication (three pulses of 6s). Samples were centrifuged for 5 min at
30
31 13,000 g. The absorbance of the supernatant was determined at 570 nm in a microplate reader.
32
33
34
35
36 Results were expressed as fold of control.
37
38
39

40 4.8. Statistical analysis

41
42 Data are expressed as mean \pm standard error (SE) from at least 3 independent
43
44 experiments. The significance of differences among different groups was determined by one-
45
46 way ANOVA, followed by Student Newman-Keuls as post-hoc test. $P < 0.05$ was considered
47
48 to be statistically significant.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

The authors would like to thank Professor J. N. Fang for the help in providing LBA. This work is supported by the Research Fund for the Control of Infectious Disease (05050032) from Food and Health Bureau, General Research Grant (7552/06M) and NSFC/RGC Joint Research Scheme (N_HKU707/07M) from Research Grant Council, HKU Alzheimer's Disease Research Network and HKU Seed Funding for Basic Research (200711159028) to RCCC. Also, the work is supported by Azalea 1972 Endowed Fund. WHY would like to thank for the support from the Department of Chemistry. YSH is supported by the Graduate School, MSY is supported by Postdoctoral Fellowship, The University of Hong Kong.

Figure legends

Fig. 1. LBA protected cortical neurons from glutamate-induced neurotoxicity. Rat primary cortical neurons were treated with different dosages of LBA for 1 h and then co-incubated with 30 or 60 μM glutamate for 24 h. The level of neuronal cell death in culture treated with (a) LBA only (c) LBA and 30 μM glutamate and (e) LBA and 60 μM glutamate was accessed by LDH assay. Cultured neurons have a normal turnover with baseline of LDH of $12.5 \pm 0.5\%$ of total lysis. The level of apoptosis in culture treated with (b) LBA only (d) LBA and 30 μM glutamate and (f) LBA and 60 μM glutamate was accessed by colorimetric caspase-3 like activity assay. The specific activity of caspase-3 was 0.042 ± 0.007 pmol/min/ μg of protein in the control group. Data represent mean \pm SE from at least 3 independent experiments. The significance of differences among treatment groups was determined by one-way ANOVA, followed by Student Newman-Keuls as post-hoc test. $\#p < 0.001$ compared to control. $\Delta p < 0.05$ compared to cultures treated with 30 μM glutamate. $**p < 0.001$ compared to cultures treated with 60 μM glutamate. $*p < 0.05$ compared to cultures treated with 60 μM glutamate.

Fig. 2. LBA preserved morphological changes in glutamate-treated groups. Neurons were incubated in the absence or presence of glutamate for 24 h. LBA was added 1h before the addition of glutamate. Photographs shows phase-contrast images of representative fields of cells after various treatments. (a) Control, (b) 30 μM glutamate, (c) 60 μM glutamate, circled areas indicate fragmented neuritis, (d) 500 $\mu\text{g/ml}$ LBA, (e) 500 $\mu\text{g/ml}$ LBA + 30 μM glutamate and (f) 500 $\mu\text{g/ml}$ LBA + 60 μM glutamate. There were no obvious morphological difference between the control and LBA alone treatment groups, while LBA preserved the morphology of neurons that exposed to glutamate.

1
2
3
4 **Fig. 3.** Neuroprotective effects of LBA against glutamate toxicity were comparable to that
5
6 provided by memantine. Neurons were treated with LBA or memantine for 1 h prior to the
7
8 addition of glutamate for 24 h. The protective effects of LBA and memantine against
9
10 glutamate-induced cell death and apoptosis were accessed by (a) LDH assay and (b) caspase-3
11
12 like activity assay. Data represent mean \pm SE from at least 3 independent experiments. The
13
14 significance of differences among treatment groups was determined by one-way ANOVA,
15
16 followed by Student Newman-Keuls as post-hoc test. # $p < 0.001$ compared to control.
17
18 ** $p < 0.001$ compared to cultures treated with 60 μ M glutamate. * $p < 0.05$ compared to cultures
19
20 treated with 60 μ M glutamate. $\Delta\Delta p < 0.001$ compared to cultures treated with 30 μ M glutamate.
21
22 $\Delta p < 0.05$ compared to cultures treated with 30 μ M glutamate.
23
24
25
26
27
28

29 **Fig. 4.** Effects of post-treatment of LBA on glutamate neurotoxicity. Neurons were exposed
30
31 to glutamate for 1 h prior to LBA for another 23 h. Release of LDH was measured in (a)
32
33 neurons treated with LBA and 30 μ M glutamate (c) LBA and 60 μ M glutamate. Level of
34
35 apoptosis in (b) neurons treated with LBA and 30 μ M glutamate (d) LBA and 60 μ M
36
37 glutamate was accessed by measuring the caspase-3 like activity. Data were analyzed by one-
38
39 way ANOVA for multiple comparisons, followed by Student Newman-Keuls as post-hoc test.
40
41 # $p < 0.001$ compared to control. $\Delta\Delta p < 0.001$ compared to cultures treated with 30 μ M glutamate.
42
43 $\Delta p < 0.05$ compared to cultures treated with 30 μ M glutamate. * $p < 0.05$ compared to cultures
44
45 treated with 60 μ M glutamate.
46
47
48
49
50
51

52 **Fig. 5.** Effects of LBA against NMDA neurotoxicity. LBA was added into the culture for 1 h
53
54 and then co-incubated with 40 or 60 μ M NMDA for 24 h. (a) LDH assay and (b) caspase-3
55
56 like activity assay were performed. Data represent mean \pm SE from at least 3 independent
57
58 experiments. The significance of differences among treatment groups was determined by one-
59
60
61
62
63
64
65

1
2
3
4 way ANOVA, followed by Student Newman-Keuls as post-hoc test. # $p < 0.001$ compared to
5
6 control. ## $p < 0.05$ compared to control. $\Delta\Delta p < 0.001$ compared to cultures treated with 40 μM
7
8 NMDA. ** $p < 0.001$ compared to cultures treated with 60 μM NMDA.
9

10
11
12
13 **Fig. 6.** LBA could not protect neurons against H_2O_2 -induced toxicity. Neurons were treated
14
15 with LBA for 1 h prior to the exposure to H_2O_2 for 24 h. (a) LDH assay and (b) caspase-3 like
16
17 assay were carried out to examine its protective effect. Data represent mean \pm SE from at least
18
19 3 independent experiments. The significance of differences among treatment groups was
20
21 determined by one-way ANOVA, followed by Student Newman-Keuls as post-hoc test.
22
23 # $p < 0.001$ compared to control. * $p < 0.05$ compared to cultures treated with H_2O_2 .
24
25
26
27
28

29
30 **Fig. 7.** LBA did not attenuate glutamate-induced production of ROS. Neurons were treated
31
32 with LBA for 1 h prior to the exposure to 60 μM glutamate for 2 h. NBT reduction assay were
33
34 performed to access the level of intracellular ROS. Data represent mean \pm SE from at least 3
35
36 independent experiments. The significance of differences among treatment groups was
37
38 determined by one-way ANOVA, followed by Student Newman-Keuls as post-hoc test.
39
40 # $p < 0.001$ compared to control. * $p < 0.05$ compared to cultures treated with glutamate only.
41
42
43
44

45
46 **Fig. 8.** LBA suppressed the phosphorylation of JNK in glutamate-treated groups. Neurons
47
48 were treated with indicated dosages of LBA for 1 h prior to the exposure to 60 μM glutamate
49
50 for 2 h. Cell were harvested for measurement of phosphorylated JNK and non-phosphorylated
51
52 JNK by Western blotting. β -Actin was used as internal control. The images of Western blots
53
54 films were scanned and quantified with Image J. Data showed the ratio of p-JNK to JNK.
55
56 Data represent mean \pm SE from at least 3 independent experiments. Statistical analysis was
57
58
59
60
61
62
63
64
65

performed with one-way ANOVA, followed by Student Newman-Keuls as post-hoc test.

#p<0.05 compared to control. *p<0.05 compared to cultures treated with 60 μ M glutamate.

References

- Abib RT, Quincozes-Santos A, Nardin P, Wofchuk ST, Perry ML, Gonçalves. C.A., Gottfried C (2008) Epicatechin gallate increases glutamate uptake and S100B secretion in C6 cell lineage. *Mol Cell Biochem.* 310:153-158.
- Amagase H, Nance DM (2008) A Randomized, Double-Blind, Placebo-Controlled, Clinical Study of the General Effects of a Standardized *Lycium barbarum* (Goji) Juice, GoChi. *J Altern Complement Med* In press
- Amodio R, Esposito E, De RC, Bellavia V, Amodio E, Carruba G, (2006) Red wine extract prevents neuronal apoptosis in vitro and reduces mortality of transgenic mice. *Ann NY Acad Sci* 1089,:88-97.
- Arthur PG, Matich GP, Pang WW, Yu DY, Bogoyevitch MA, (2007) Necrotic death of neurons following an excitotoxic insult is prevented by a peptide inhibitor of c-jun N-terminal kinase. *J Neurochem* 102:65-76.
- Arundine M, Tymianski M, (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. *Cell Mol Life Sci* 61:657-668.
- Baethmann A, Staub F, Kempfski O, Plesnila N, Chang RCC, Schnezder GH, Eriskat J, Stoffel, M, Ringel F, (1996) Glutamate enhances brain damage from ischemia and trauma. In:"Maturation Phenomenon in cerebral ischemia II", (Ito U, ed) Berlin, Springer-Verlag, pp43-51.
- Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny, C, (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nat Med* 9:1180-1186.
- Chan HC, Chang RCC, Koon-Ching IA, Chiu K, Yuen WH, Zee SY, So KF, (2007) Neuroprotective effects of *Lycium barbarum* Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. *Exp Neurol* 203:269-273.
- Chang RCC, So KF, (2008) Use of Anti-aging Herbal Medicine, *Lycium barbarum*, Against Aging-associated Diseases. What Do We Know So Far? *Cell Mol Neurobiol* 28:643-652.
- Chang RCC, Suen KC, Ma CH, Elyaman W, Ng HK, Hugon J, (2002) Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2 α in neuronal degeneration. *J Neurochem* 83:1215-1225.
- Chao J, Yu MS, Ho YS, Wang M, Chang RCC, (2008) Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. *Free Rad Biol Med* 45:1019-26.
- Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, Chuang DM, (2003) Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. *J Neurochem* 84:566-575.

- 1
2
3
4 Chi CW, Wang CN, Lin YL, Chen CF, Shiao YJ, (2005) Tournefolic acid B methyl ester
5 attenuates glutamate-induced toxicity by blockade of ROS accumulation and abrogating
6 the activation of caspases and JNK in rat cortical neurons. *J Neurochem* 92:692-700.
7
- 8 Chicoine LM, Bahr BA, (2007) Excitotoxic protection by polyanionic polysaccharide:
9 evidence of a cell survival pathway involving AMPA receptor-MAPK Interactions. *J*
10 *Neurosci Res* 85:294-302.
11
- 12 Chicoine LM, Suppiramaniam V, Vaithianathan T, Gianutsos G, Bahr BA, (2004) Sulfate-
13 and size-dependent polysaccharide modulation of AMPA receptor properties. *J Neurosci*
14 *Res* 75:408-416.
15
- 16 Choi DW, (1988) Glutamate neurotoxicity and diseases of the nervous system. *Neuron* 1:623-
17 634.
18
- 19 Choi DW, Maulucci-Gedde M, Kriegstein AR, (1987) Glutamate neurotoxicity in cortical cell
20 culture. *J Neurosci* 7:357-368.
21
- 22 Choi SH, Lee DY, Kim SU, Jin BK, (2005) Thrombin-induced oxidative stress contributes to
23 the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. *J*
24 *Neurosci* 25:4082-4090.
25
- 26 Coyle JT, Puttfarcken P, (1993) Oxidative stress, glutamate, and neurodegenerative disorders.
27 *Science* 262: 689-695.
28
- 29 Dicou E, Rangon CM, Guimiot F, Spedding M, Gressens P, (2003) Positive allosteric
30 modulators of AMPA receptors are neuroprotective against lesions induced by an
31 NMDA agonist in neonatal mouse brain. *Brain Res* 970:221-225.
32
- 33 Fang X, Yu MM, Yuen WH, Zee SY, Chang RCC, (2005) Immune modulatory effects of
34 *Prunella vulgaris* L. on monocytes/macrophages. *Intl J Mol Med* 16:1109-1116.
35
- 36 Freudenthaler S, Pantev M, (2008) Dose-response analysis to support dosage
37 recommendations for memantine, *Naunyn-Schmiedebergs Arch Pharmacol* 353, Suppl.:
38 R159
39
- 40 Gardoni F, Di LM, (2006) New targets for pharmacological intervention in the glutamatergic
41 synapse. *Eur J Pharmacol* 545:2-10.
42
- 43 Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D, (2002) Antioxidant therapy in acute
44 central nervous system injury: current state. *Pharmacol Rev* 54:271-284.
45
- 46 Gladstone DJ, Black SE, Hakim AM, (2002) Toward wisdom from failure: lessons from
47 neuroprotective stroke trials and new therapeutic directions. *Stroke* 33:2123-2136.
48
- 49 Golde TE, (2006) Disease modifying therapy for AD? *J Neurochem* 99:689-707.
50
- 51 Ho YS, Yu MS, Lai CS, So KF, Yuen WH, Chang RCC, (2007) Characterizing the
52 neuroprotective effects of alkaline extract of *Lycium barbarum* on beta-amyloid peptide
53 neurotoxicity. *Brain Res* 1158C:123-134.
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 Hyrc K, Handran SD, Rothman SM, Goldberg MP, (1997) Ionized intracellular calcium
5 concentration predicts excitotoxic neuronal death: observations with low-affinity
6 fluorescent calcium indicators. *J Neurosci* 17:6669-6677.
7
- 8 Johnson JW, Kotermanski SE, (2006) Mechanism of action of memantine. *Curr Opin*
9 *Pharmacol* 6:61-67.
10
- 11 Kogo J, Takeba Y, Kumai T, Kitaoka Y, Matsumoto N, Ueno S, Kobayashi S, (2006)
12 Involvement of TNF-alpha in glutamate-induced apoptosis in a differentiated neuronal
13 cell line. *Brain Res* 1122:201-208.
14
- 15 Kornhuber J, Kennepohl EM, Bleich S, Wiltfang J, Kraus T, Reulbach U, Meineke I, (2007)
16 Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic
17 approach. *Clin Pharmacokinet* 46:599-612.
18
- 19 Kornhuber J, Quack G, (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-
20 D-aspartate (NMDA) receptor antagonist memantine in man. *Neurosci Lett* 195:137-
21 139.
22
- 23 Lai SW, Yu MS, Yuen WH, Chang RCC, (2006) Novel neuroprotective effects of the
24 aqueous extracts from *Verbena officinalis* Linn. *Neuropharmacology* 50:641-650.
25
- 26 Lai SW, Yu MS, Yuen WH, So KF, Zee SY, Chang RCC, (2008) Antagonizing beta-amyloid
27 peptide neurotoxicity of the anti-aging fungus *Ganoderma lucidum.*, *Brain Res* 1190:
28 215-224.
29
- 30 Lauri SE, Kaukinen S, Kinnunen T, Ylinen A, Imai S, Kaila K, Taira T, Rauvala H, (1999)
31 Regulatory role and molecular interactions of a cell-surface heparan sulfate
32 proteoglycan (N-syndecan) in hippocampal long-term potentiation. *J Neurosci* 19:1226-
33 1235.
34
- 35 Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H, (1998)
36 Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid
37 precursor protein secretion and heparin binding to beta-amyloid peptide. *J Neurochem*
38 70:736-744.
39
- 40 Li XM, Ma YL, Liu XJ, (2006) Effect of the *Lycium barbarum* polysaccharides on age-
41 related oxidative stress in aged mice. *J Ethnopharmacol* 111:504-511.
42
- 43 Lipton SA, (2005) The molecular basis of memantine action in Alzheimer's disease and other
44 neurologic disorders: low-affinity, uncompetitive antagonism. *Curr Alzheimer Res*
45 2:155-165.
46
- 47 Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J, (2002)
48 The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. *Thromb*
49 *Res* 105:447-453.
50
- 51 McDonald DR, Brunden KR, Landreth GE, (1997) Amyloid fibrils activate tyrosine kinase-
52 dependent signaling and superoxide production in microglia. *J Neurosci* 17:2284-2294.
53
- 54 Miyamoto E, (2006) Molecular mechanism of neuronal plasticity: induction and maintenance
55 of long-term potentiation in the hippocampus. *J Pharmacol Sci* 100:433-442.
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 Parsons CG, Gilling KE, Jatzke C, (2008) Memantine does not show intracellular block of the
5 NMDA receptor channel. *Eur J Pharmacol* 587:99-103.
6
- 7 Pietrzik C, Behl C, (2005) Concepts for the treatment of Alzheimer's disease: molecular
8 mechanisms and clinical application. *Intl J Exp Pathol* 86:173-185.
9
- 10 Portera-Cailliau C, Price DL, Martin LJ, (1997) Excitotoxic neuronal death in the immature
11 brain is an apoptosis-necrosis morphological continuum. *J Comp Neurol* 378:70-87.
12
- 13 Schubert D, Piasecki D, (2001) Oxidative glutamate toxicity can be a component of the
14 excitotoxicity cascade. *J Neurosci* 21:7455-7462.
15
- 16 Seveg MG, (1934) Deproteinization and removal of capsular polysaccharides, *Biochem Z*
17 273:419-423.
18
- 19 Shigeri Y, Seal RP, Shimamoto K, (2004) Molecular pharmacology of glutamate transporters,
20 EAATs and VGLUTs. *Brain Res. Brain Res Rev* 45:250-265.
21
- 22 Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH, (2006) Cystine/glutamate
23 exchange modulates glutathione supply for neuroprotection from oxidative stress and
24 cell proliferation. *J Neurosci* 26:10514-10523.
25
- 26 Sinnarajah S, Suppiramaniam V, Kumar KP, Hall RA, Bahr BA, Vodyanoy V, (1999)
27 Heparin modulates the single channel kinetics of reconstituted AMPA receptors from
28 rat brain. *Synapse* 31:203-209.
29
- 30 Sotogaku N, Tully SE, Gama CI, Higashi H, Tanaka M, Hsieh-Wilson LC, Nishi A, (2007)
31 Activation of phospholipase C pathways by a synthetic chondroitin sulfate-E
32 tetrasaccharide promotes neurite outgrowth of dopaminergic neurons. *J Neurochem*
33 103:749-760.
34
- 35 Suen KC, Lin KF, Elyaman W, So KF, Chang RCC, Hugon J, (2003) Reduction of calcium
36 release from the endoplasmic reticulum could only provide partial neuroprotection
37 against beta-amyloid peptide toxicity. *J Neurochem* 87:1413-1426.
38
- 39 Suppiramaniam V, Vaithianathan T, Manivannan K, Dhanasekaran M, Parameshwaran K,
40 Bahr BA, (2006) Modulatory effects of dextran sulfate and fucoidan on binding and
41 channel properties of AMPA receptors isolated from rat brain. *Synapse* 60:456-464.
42
- 43 Tan S, Schubert D, Maher P, (2001) Oxytosis: A novel form of programmed cell death. *Curr*
44 *Top Med Chem* 1:497-506.
45
- 46 Tan S, Wood M, Maher P, (1998) Oxidative stress induces a form of programmed cell death
47 with characteristics of both apoptosis and necrosis in neuronal cells. *J Neurochem*
48 71:95-105.
49
- 50 Won SJ, Kim DY, Gwag BJ, (2002) Cellular and molecular pathways of ischemic neuronal
51 death. *J Biochem Mol Biol* 35:67-86.
52
- 53 Wu X, Zhu D, Jiang X, Okagaki P, Mearow K, Zhu G, McCall S, Banaudha K, Lipsky RH,
54 Marini AM, (2004) AMPA protects cultured neurons against glutamate excitotoxicity
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-
5 regulated kinase to upregulate BDNF gene expression. *J Neurochem* 90:807-818.
6

7 Yazawa K, Kihara T, Shen H, Shimmyo Y, Niidome T, Sugimoto H, (2006) Distinct
8 mechanisms underlie distinct polyphenol-induced neuroprotection. *FEBS letters*
9 580:6623-6628.
10

11 Yu MS, Ho YS, So KF, Yuen WH, Chang RCC, (2006) Cytoprotective effects of *Lycium*
12 *barbarum* against reducing stress on endoplasmic reticulum. *Intl J Mol Med* 17:1157-
13 1161.
14

15 Yu MS, Lai SW, Lin KF, Fang JN, Yuen WH, Chang RCC, (2004) Characterization of
16 polysaccharides from the flowers of *Nerium indicum* and their neuroprotective effects.
17 *Intl J Mol Med* 14:917-924.
18

19 Yu MS, Leung SK, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RCC, (2005)
20 Neuroprotective effects of anti-aging oriental medicine *Lycium barbarum* against beta-
21 amyloid peptide neurotoxicity. *Exp Gerontol* 40:716-727.
22

23 Yu MS, Wong AY, So KF, Fang JN, Yuen WH, Chang RCC, (2007) New polysaccharide
24 from *Nerium indicum* protects neurons via stress kinase signaling pathway. *Brain Res*
25 1153:221-230.
26

27 Zhang Y, Bhavnani BR, (2006) Glutamate-induced apoptosis in neuronal cells is mediated via
28 caspase-dependent and independent mechanisms involving calpain and caspase-3
29 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by
30 equine estrogens. *BMC Neurosci* 7:49.
31

32 Zhang Y, Lu X, Bhavnani BR, (2003) Equine estrogens differentially inhibit DNA
33 fragmentation induced by glutamate in neuronal cells by modulation of regulatory
34 proteins involved in programmed cell death. *BMC Neurosci* 4:32.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65









Fig.1




Fig. 2





Fig. 3







Fig.4





Fig.5





Fig. 6




Fig. 7





Fig. 8